This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by University of Virginia.
Recruitment status was:  Recruiting
National Institutes of Health (NIH)
Information provided by:
University of Virginia Identifier:
First received: February 27, 2008
Last updated: August 6, 2008
Last verified: August 2008
The purpose of this study is to determine if contrast enhanced ultrasound (CEU) using microbubbles, is useful in assessing changes in kidney blood flow.

Condition Intervention
Kidney Drug: perflutren lipid microspheres

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound

Resource links provided by NLM:

Further study details as provided by University of Virginia:

Estimated Enrollment: 20
Study Start Date: June 2006
Estimated Study Completion Date: December 2009
Intervention Details:
    Drug: perflutren lipid microspheres
    1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
    Other Name: Definity

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adults
  • Males and females
  • Ages 18-65 years old

Exclusion Criteria:

  • Pregnancy or lactation
  • H/o kidney disease
  • H/o congestive heart failure, ischemic heart disease, severe pulmonary disease or allergy to the drug
  • H/o any cardiovascular disease
  • Abnormal liver function (liver function tests out of specified ranges)
  • Screening urinalysis which indicates infection or inflammation
  • Taking regular medications (except for over-the-counter vitamins or hormonal contraceptives.)
  • Taking supplements, like protein shakes
  • Unwilling or unable to eat chicken (used as protein meal)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00631553

Contact: Kambiz Kalantarinia, MD 434 924 5125
Contact: Lori Ratliff, RN ANP 434 924 5820 ext 4-1572

United States, Virginia
University of Virginia Health System Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Kalantarinia   
Contact: Ratliff   
Principal Investigator: Kambiz Kalantarinia, MD         
Sponsors and Collaborators
University of Virginia
National Institutes of Health (NIH)
Principal Investigator: Kambiz Kalantarinia, MD University of Virginia
  More Information

Responsible Party: Kambiz Kalantarinia MD Assitant Professor of Medicine, University of Virginia Dept of Medicine Identifier: NCT00631553     History of Changes
Other Study ID Numbers: 12014
Study First Received: February 27, 2008
Last Updated: August 6, 2008 processed this record on September 21, 2017